News Blog

CAC2’s weekly update for news and community highlights.

[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: For many patients, one of the most antagonizing parts of a hospital visit is paying for parking. Those parking

[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: “I’d like to introduce you to Josh. . .  Josh, a sound engineer, is also a childhood cancer

[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: CAC2 Member Mary Beth Collins explains the importance of the new FDA approval of Pedmark:  “With the FDA’s

[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: CAC2 Member Joe Baber reflects on the Gabriella Miller Kids First 2.0 legislation pending in Congress:  “We’re all

[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC) in

[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: November is National Family Caregivers Month.  The President Joe Biden honored family caregivers for all they do for

[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: CBS “Sunday Morning” contributor Kelefa Sanneh talked with CAC2 Members Kari and Tom Whitehead and their daughter Emily

Assorted News from the Last Week: Nearly one in four families of pediatric patients with acute lymphoblastic leukemia (ALL) enrolled in a clinical trial experienced

[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: Pedmark (sodium thiosulfate) is now available to reduce the risk of ototoxicity associated with cisplatin in pediatric patients